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th dansyAbstract A reliable, sensitive and selective spectroﬂuorimetric method has been developed for the
determination of certain antidepressant drugs namely sertraline hydrochloride, ﬂuoxetine
hydrochloride, paroxetine hydrochloride, amineptine hydrochloride and bupropion hydrochloride
in pure forms, pharmaceutical formulation and human plasma. The method is based on the reaction
of investigated drugs with 5-(dimethylamino) naphthalene-1-sulfonyl chloride (dansyl chloride) in
the presence of 0.5 M sodium carbonate to yield highly ﬂuorescent derivatives, measured at
450 nm (excitation at 347 nm). The different experimental parameters affecting the development
and stability of the reaction products were carefully studied and optimized. The calibration plots
were constructed over the range of 0.02–0.14 lg mL1. The proposed method was successfully
applied for analysis of cited drugs in dosage forms. The high sensitivity of the proposed method
allows the determination of investigated drugs in spiked and real human plasma. Statistical compar-
isons of the results with the reference methods show an excellent agreement and indicate no signif-
icant difference in accuracy and precision.
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Depression is a chronic or recurrent illness that affects both
economic and social functions of patients and can eventually
lead to suicidal behaviors. Antidepressant medications have
been used in the treatment of major depressive disorders
(Parﬁtt, 2002). In the last years, prescriptions of antidepres-
sants have increased dramatically in Egypt. Sertraline, paroxe-
tine, ﬂuoxetine, bupropion and amineptine are commerciallying Saud University.
protocol for antidepressant drugs in dosage forms and human plas-
emistry (2014), http://dx.doi.org/10.1016/j.arabjc.2013.12.015
2 M.A. Omar et al.available antidepressant drugs extensively used in Egypt. The
chemical structure of the studied antidepressant drugs in this
work is shown in Table 1.
Several methods have been published for the determination
of these drugs in bulk or in different pharmaceutical formula-
tions as well as in biological ﬂuids, these methods include
volumetric methods (Bueno et al., 2000; Delazzeri, 2005), spec-
troscopic methods (Basavaiah and Sameer, 2010; Darwish,
2005; Darwish and Refaat, 2006; Mohamed et al., 2007; Onal
et al., 2005, 2006; Sameer and Basavaiah, 2011), electrochem-
ical methods (Atta-Politou et al., 2001; Nouws et al., 2006),
chromatographic methods (Berzas Nevado et al., 2006; Sbarra
et al., 1979, 1981; Tsaconas et al., 1989; Zainaghi et al., 2003;
Zhu and Neirinck, 2002) and capillary electrophoretic methods
(Labat et al., 2002; Mandrioli et al., 2002).
The wide use of these drugs necessitates the development of
a rapid, accurate, sensitive, applicable and cheaper method for
their determination in pure forms, pharmaceuticalTable 1 Structural Formula of the studied antidepressant drugs.
Name Chemical name [1]
Sertraline
hydrochloride
(1S,4S)-4[3,4-dichloroph
methyl-1-naphthylamin
Paroxetine
hydrochloride
(3S,4R)-3-[(1,3-Benzodio
ﬂuorophenyl) piperidine
Fluoxetine
hydrochloride
(3RS)-N-methyl-3-pheny
phenoxy] propane-1-ami
Bupropion
hydrochloride
1-(3-Chlorophenyl)-2-[(1
propanone hydrochlorid
Amineptine
hydrochloride
Dihydro-10,1I-dibenzo[a
heptanoic acid
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study, we describe a novel sensitive spectroﬂuorimetric method
for the determination of these drugs depending on the presence
of a secondary amine moiety.2. Experimental
2.1. Apparatus
- A Perkin Elmer LS 45 Luminescence spectrometer (United
Kingdom) connected to an IBM PC computer loaded with
the FL WINLAB software.
- Spectronic Genesys 2PC. Ultraviolet/Visible spectro-
photometer (Milton Roy Co, USA) with a matched 1 cm
quartz cell connected to IBM computer loaded with win-
spec application software.Structure
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Spectroﬂuorimetric protocol 3- Milwakee SM 101 pH meter, Portugal.
- Digital analytical balance (AG 29, Meltter Toledo, Glattb-
rugg, Switzerland).
- Laboratory centrifuge 4000 c/s (Bremsen ECCO,
Germany).
2.2. Materials and reagents
All the chemicals used throughout this work were of analytical
reagent grade and their solutions were prepared with double
distilled water. Samples of investigated drugs were generously
supplied by their respective manufacturers and were used with-
out further puriﬁcation.
* Sertraline hydrochloride (Pﬁzer Egypt, S.A.E., Cairo,
Egypt), ﬂuoxetine hydrochloride (EIPICO, El Asher Ram-
adan City, Cairo, Egypt), paroxetine hydrochloride (Pha-
raonia Pharmaceuticals Pharo Pharma, Alexandria,
Egypt), amineptine hydrochloride (Servier Egypt Industries
Limited, 6th October City, Giza, Egypt) and bupropion
hydrochloride (Adwia Co., El Asher Ramadan City, Cairo,
Egypt).
* 5-(Dimethylamino)naphthalene-1-sulfonyl chloride (dansyl
chloride), was purchased from Sigma (St. Louis, USA). A
stock solution containing 3.71 · 103 M of dansyl chloride
was freshly prepared in acetone and was further diluted
with the same solvent to obtain 3.71 · 105 M solution.
* Sodium carbonate (El Nasr chemical co., Abu Zabbal,
Egypt); 0.5 M aqueous solution (pH 10) was prepared by
dissolving 13.3 g in 250.0 mL of double distilled water.
* Acetone was purchased from El Nasr chemical co., Abu
Zabbal, Egypt.
* Plasma was kindly provided by Minia Hospital for psychi-
atric medicine and the study was performed and permitted
according to institutional guidelines. Plasma samples were
kept frozen until assay after gentle thawing.
* Chloroform (Merck, Darmstadt, Germany).
2.3. Pharmaceutical formulations
The following available commercial preparations were
analyzed;
Lustral

tablets (Pﬁzer Egypt, S.A.E., Cairo, Egypt) labeled
to contain 50.0 mg sertraline per tablet. Flutin

capsules (EIP-
ICO, El Asher Ramadan City, Cairo, Egypt) labeled to con-
tain 20.0 mg ﬂuoxetine per capsule. Paxetin

tablets
(Pharaonia Pharmaceuticals Pharo Pharma, Alexandria,
Egypt) labeled to contain 20.0 mg of paroxetine per tablet.
Survector

tablets (Servier Egypt Industrial Limited, 6th Octo-
ber City, Giza, Egypt) labeled to contain 100.0 mg of aminep-
tine hydrochloride per tablet. Abstain

tablets (Adwia Co., El
Asher Ramadan City, Cairo, Egypt) labeled to contain
150.0 mg of bupropion per tablet.
2.4. Preparation of standard solution
An accurate weight 40.0 mg of hydrochloric salts of each
investigated CNS drugs was transferred into a 100-mL separat-
ing funnel containing about 20 mL distilled water. ThePlease cite this article in press as: Omar, M.A. et al., Spectroﬂuorimetric
ma through derivatization with dansyl chloride. Arabian Journal of Chresultant solution was rendered distinctly alkaline by a drop
wise addition of 33% w/v aqueous ammonia then the librated
free base was extracted with three potions of 20 mL chloro-
form and the combined chloroformic extracts were ﬁltered
through anhydrous sodium sulfate supported on Whitman ﬁl-
ter paper into a 100-mL volumetric ﬂak. The ﬁlter paper was
washed thoroughly with two portions of 5 mL chloroform.
The combined extracts and washings were diluted to volume
with chloroform to provide a standard solution containing
400.0 lg mL1. 10.0 mL of chloroform extract was further dis-
tilled under vacuum and the oily residue was dissolved in
20.0 mL of mixture of acetone 0.5 M sodium carbonate
(3:2) and transferred into a 100 mL volumetric ﬂask then com-
pleted to the volume with the same solvent mixture to obtain a
standard solution containing 40.0 lg mL1. This solution was
further diluted with the same solvent mixture to prepare work-
ing standard solutions containing 0.20–1.40 lg mL1 (200.0–
1400.0 ng mL1). The standard solutions were stable for
7 days when kept in the refrigerator.
2.5. General procedure
Into a series of 10-mL volumetric ﬂasks, 1.0 mL of working
standard solution of drugs was transferred over the cited con-
centration range of 0.20–1.40 lg mL1 and 0.7 mL of
3.71 · 105 M of dansyl chloride reagent was added and mixed
well. The reaction mixture was left for 25 min, and then com-
pleted to the volume with acetone. The ﬂuorescence intensity
of the reaction products was measured at 450 nm after excita-
tion at 347 nm. Blank experiment was carried out simulta-
neously. The relative ﬂuorescence intensity of each sample
solution for each investigated drug was accurately measured
and plotted against the ﬁnal concentration of the drug
(ng mL1) to get the calibration graphs.
2.5.1. Determination of the studied drugs in pharmaceutical
formulations (tablets and capsules)
A quantity of ﬁnely powdered twenty tablets or mixed capsule
contents equivalent to 100.0 mg of active component was
transferred to a 50-mL volumetric ﬂask, sonicated for about
10 min with about 30 mL double distilled water then the vol-
ume was made up with distilled water, mixed well and ﬁltrated.
The ﬁrst portion of the ﬁltrate was discarded; 20 mL of the
clear solution was transferred quantitatively to a 100-mL sep-
arating funnel. The contents of the funnel were rendered alka-
line with a drop wise addition 33% w/v aqueous ammonia
solution, and the procedure was completed as described for
preparation of the stock standard solutions.
2.5.2. Procedure for spiked human plasma
5.0 mL of drug free human blood sample was taken from
healthy volunteers into a heparinized tube, centrifuged at
3000 rpm for 30 min. Then 1.0 mL of the supernatant (plasma)
was spiked with 1.0 mL of investigated drugs (2–14 lg mL1).
2.0 mL of acetonitrile was added as a precipitating agent for
protein then centrifuged at 4000 rpm for about 20 min. The
supernatant was rendered alkaline by adding 1.0 mL of 33%
w/v aqueous ammonia and then extract 3 times with
3 · 3 mL of chloroform. The combined extracts were evapo-
rated to dryness under vacuum. The residue was dissolved
and diluted to volume with a mixture of 6.0 mL of acetoneprotocol for antidepressant drugs in dosage forms and human plas-
emistry (2014), http://dx.doi.org/10.1016/j.arabjc.2013.12.015
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Figure 1 Fluorescence spectra where A and B are excitation and
emission spectra of blank, while C and D are excitation and
emission spectra of sertraline, as a representative example,
(140.0 ng mL1) with dansyl chloride.
4 M.A. Omar et al.and 4.0 mL of 0.5 M of sodium carbonate solution. Aliquots
covering the working concentration range were transferred
into 10-mL volumetric ﬂasks. Then the general procedure
was followed. A blank value was determined by treating the
drug free blood sample in the same manner.
2.5.3. Procedure for real human plasma
For ﬂuoxetine, 20.0 mg was taken orally once daily by three
healthy human volunteers for 4 weeks. 5.0 mL of human blood
sample was taken by using heperinized tube after an average of
6 h following the last oral administration and then centrifuged
at 3000 rpm for 30 min. Then 3.0 mL of plasma obtained was
treated with 2.0 mL of acetonitrile as precipitating agent for
protein then centrifuged at 4500 rpm for about 20 min. The
supernatant was rendered alkaline by adding 1.0 mL of 33%
w/v aqueous ammonia and then extract 3 times with 3 · 3 mL
of chloroform. The combined extracts were evaporated to dry-
ness. The residue was dissolved and diluted to volume with a
mixture of 6.0 mL of acetone and 4.0 mL of 0.5 M of sodium
carbonate solution. Then the general procedure was followed.
For paroxetine, 40.0 mg was taken orally once daily by
three healthy human volunteers for 14 days. 10.0 mL of human
blood sample was taken by using heperinized tube after an
average of 12 h following the last oral administration and then
centrifuged at 3000 rpm for 30 min. Then 6.0 mL of plasma
obtained was treated with 4.0 mL of acetonitrile as precipitat-
ing agent for protein and then centrifuged at 4500 rpm for
about 20 min. Then the procedure was followed as described
for ﬂuoxetine.
For bupropion, 150.0 mg was taken orally every 12 h by
three healthy human volunteers for 14 days. 5.0 mL of human
blood sample was taken by using heperinized tube after an
average of 6 h following the last oral administration. Then
the procedure was followed as described for ﬂuoxetine.
For sertraline, 50.0 mg was taken orally once daily by three
healthy human volunteers for 14 days. 5.0 mL of human blood
sample was taken by using heperinized tube after an average of
12 h following the last oral administration. Then the procedure
was followed as described for ﬂuoxetine.
For Amineptine, 100.0 mg was taken orally twice daily by
three healthy human volunteers for 7 days. 5.0 mL of human
blood sample was taken by using heperinized tube at 8th day
after an average of 1 h following the last oral administration.
Then the procedure was followed as described for ﬂuoxetine.
3. Results and discussion
Dansyl chloride, is an important and widely used ﬂuorescence
reagent, was ﬁrst introduced for the determination of some
primary and secondary amines, imidazoles, phenol, etc. (Ayad
and el-Hay, 1984; Frei-Hausler and Frei, 1973; Pu¨tter, 1979).
In the recent reports, dansyl chloride was further used as a
ﬂuorogenic reagent for determination of some pharmaceutical
compounds (Cruces-Blanco et al., 2000; Houdier et al., 2000;
Lucca et al., 2000).
3.1. Fluorescence spectrum
The ﬂuorescence spectra of the sertraline as a representative
example for investigated drugs in its reaction with dansyl chlo-
ride forming a highly intense yellow ﬂuorescent derivative withPlease cite this article in press as: Omar, M.A. et al., Spectroﬂuorimetric
ma through derivatization with dansyl chloride. Arabian Journal of Chemission at 450 nm after excitation at 347 nm are shown in
Fig. 1. All other studied drugs exhibited similar spectra at
the same excitation and emission wavelengths.
3.2. Optimization of variables
The spectroﬂuorimetric properties of the ﬂuorescent products
as well as the different experimental parameters affecting the
development of the reaction product and its stability were
carefully studied and optimized. Such factors were changed
individually while the others were kept constant. The factors
include pH, acetone and sodium carbonate ratio, concentra-
tion of the reagent, type of buffer, reaction time and dilution
solvent
3.2.1. Effect of pH
The inﬂuence of pH on the relative ﬂuorescence intensity of the
reaction product was studied by using different molar concen-
trations of sodium carbonate solution (0.10–0.80 M). Maxi-
mum ﬂuorescence intensity was obtained upon using 0.5 M
sodium carbonate solution. The pH of the reaction mixture
was found to be 10. Our experimental ﬁnding is in good agree-
ment with previous reports where it was found that the opti-
mum pH for densylation labeling of most amino acids,
amines, imidazoles and phenols occurred at pH 9.5–10.5
(Seiler, 1970). The rate of dansylation process was found to in-
crease with increasing the pH value this is due to an increase in
the rate of hydrolysis of dansyl chloride into dansyl hydroxide
(Seiler, 1970). The latter shows strong ﬂuorescence and hence
interferes seriously in the determination. However, under the
proposed chosen conditions and wavelengths used, there was
no interference arising from any dansyl hydroxide formed, as
indicated by the low ﬂuorescence intensity of the reagent. Since
HCl is released during the reaction, buffering is always re-
quired. It was observed that sodium carbonate solution gave
the highest relative ﬂuorescence intensity while borate buffer
and Teorell and Stenhagen buffer gave very low ﬂuorescence
intensity. So 0.50 M sodium carbonate solution is recom-
mended in our experiment.
3.2.2. Effect of acetone: sodium carbonate ratio
By using different ratios of a mixture of acetone and 0.5 M
sodium carbonate solution, it was found that the maximumprotocol for antidepressant drugs in dosage forms and human plas-
emistry (2014), http://dx.doi.org/10.1016/j.arabjc.2013.12.015
Figure 2 Proposed reaction pathway between dansyl chloride
and investigated antidepressant drugs.
Table 3 Evaluation of accuracy of the investigated analytical
procedure at three concentration levels within the speciﬁed
range.
Drug % Recovery a
20.0 ng mL1 80.0 ng mL1 140.0 ng mL1
Sertraline 100.33 ± 1.06 99.75 ± 0.46 100.41 ± 0.27
Amineptine 99.77 ± 1.11 100.52 ± 0.28 99.99 ± 0.15
Paroxetine 99.64 ± 1.20 100.52 ± 0.46 100.20 ± 0.24
Bupropion 100.06 ± 1.26 101.02 ± 0.60 100.07 ± 0.18
Fluoxetine 100.27 ± 0.94 99.39 ± 0.62 99.45 ± 0.35
a Mean of 3 replicates ± SD.
Spectroﬂuorimetric protocol 5relative ﬂuorescence intensity was obtained upon using mix-
ture of acetone and 0.5 M sodium carbonate (3:2) solution.
3.2.3. Effect of concentration of dansyl chloride
The inﬂuence of the concentration of dansyl chloride was stud-
ied by different volumes (0.1–0.8 mL) of 3.71 · 105 M dansyl
chloride. It was found that the reaction of dansyl chloride with
investigated drugs started upon using 0.1 mL of the reagent in
the presence of sodium carbonate (pH 10.0). Increasing the
volume of the reagent, produces a proportional increase in
the ﬂuorescence intensity of the reaction product up to
0.6 mL and remains constant up to 0.8 mL after that a slight
decrease in relative ﬂuorescence intensity (RFI) occurs. There-
fore, 0.7 mL of 3.71 · 105 M dansyl chloride solution was
chosen as the optimal volume of the reagent.
3.2.4. Effect of reaction time
Different time intervals were tested. It was found that after
25 min, the reaction product reaches the highest ﬂuorescence
intensity and remains stable at room temperature for about
an additional 20 min.
3.2.5. Effect of diluting solvent
Different diluting solvents were tried to dilute the reaction
mixture throughout the study. It was found that acetone gave
the highest relative ﬂuorescence intensity. Dilution with 0.5 M
sodium carbonate solution, water, and acetone–water almost
produced very week ﬂuorescence and did not reduce the ﬂuo-
rescence intensity of the blank. While upon using acetone, the
ﬂuorescence intensity attained its highest value, this was attrib-
uted to the low ﬂuorescence value of the reagent.
3.3. Stoichiometry and mechanism of the reaction
The stoichiometry of the reaction mechanism was studied
adopting job’s method (Job, 1964) of continuous variation.
The molar ratio of dansyl chloride to each of investigated
drugs was 1:1. Based on the observed molar reactivity of theTable 2 Analytical parameters of spectroﬂuorimetric determination
Investigated drugs Linear
range (ng/mL)
Intercept (a) Standard deviati
of intercept (Sa)
Sertraline 20.0–140.0 6.14 1.45
Amineptine 20.0–140.0 3.43 1.76
Paroxetine 20.0–140.0 1.29 1.84
Bupropion 20.0–140.0 1.43 2.41
Fluoxetine 20.0–140.0 13.29 2.38
Please cite this article in press as: Omar, M.A. et al., Spectroﬂuorimetric
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group and by an analogy to similar reports dealing with the
reaction of dansyl chloride with compounds containing sec-
ondary amino groups (Pesez and Bartos, 1974), the reaction
pathway proposed is presented in Fig. 2.
3.4. Validation of the proposed method
3.4.1. Concentration range
Topic Q2A (1994) is established by conﬁrming that the analyt-
ical procedure provides a suitable degree of precision, accuracy
and linearity when applied to the sample containing amount of
analyte within or at the extreme of the speciﬁed range of the
analytical procedure (The United States Pharmacopoeia
XXV and NF XX, 2002; Topic Q2B, 1996). In this work, con-
centration ranging from 20.0 to 140.0 ng mL1 was studied for
the investigated drugs. The whole set of experiments were car-
ried out through this range to ensure the validation of the pro-
posed procedure. Linear calibration graphs were obtained for
all the studied drugs by plotting the RFI of the studied drugs
versus the drug concentration (ng mL1) within the speciﬁed
range. Linearity was indicated by a high correlation coefﬁcient
obtained. The correlation coefﬁcients (r) of the formed prod-
ucts were in the range from 0.9990 to 0.9998 indicating good
linearity, as shown in Table 2.
3.4.2. Accuracy
The United States Pharmacopoeia XXV and NF XX, 2002
was checked at three concentration levels within the speciﬁed
range; six replicate measurements were recorded at each con-
centration level. The results were recorded as percent recov-
ery ± standard deviation, as shown in Table 3. The results
obtained show the close agreement between the measured
and true values. Meanwhile, a comparison of the obtained re-
sults from the analysis of the drug products by the proposed
procedure with those obtained from the reported methodsof investigated CNS drugs with dansyl chloride.
on Slope (b) Correlation
coeﬃcient (r)
LOD (ng/mL) LOQ (ng/mL)
4.15 0.9993 1.049 3.497
3.78 0.9991 1.398 4.659
3.49 0.9990 1.582 5.272
3.31 0.9995 2.181 7.271
3.19 0.9998 2.234 7.445
protocol for antidepressant drugs in dosage forms and human plas-
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Table 4 Statistical analysis of the results obtained using the proposed and reference methods for spectroﬂuorimetric analysis of
authentic samples using dansyl chloride.
Drug Proposed methods ± SD (n= 5) Reported method8–10 ± SD (n= 5)
Sertraline 100.22 ± 0.93 101.21 ± 0.99
t= 1.62 a F= 1.16 a
Amineptine 100.40 ± 0.68 100.69 ± 1.22
t= 0.46 F= 3.27
Paroxetine 100.01 ± 1.21
t= 0.09 F= 1.06
100.08 ± 1.25
Bupropion 99.88 ± 0.77 100.16 ± 1.25
t= 0.42 F= 2.65
Fluoxetine 100.07 ± 0.78 100.74 ± 1.29
t= 0.98 F= 2.77
a Tabulated value at 95% conﬁdence limit; F= 6.338 and t= 2.306.
Table 5 Evaluation of precision using spectroﬂuorimetric
method for determination of investigated drugs with dansyl
chloride.
Drug Amount taken
(ng mL1)
% Recovery (±S.D) a
Sertraline 20 100.63 ± 0.9587
80 99.75 ± 0.3863
140 100.31 ± 0.2887
Amineptine 20 100.04 ± 1.063
80 100.58 ± 0.4646
140 99.99 ± 0.1996
Paroxetine 20 99.93 ± 1.147
80 100.57 ± 0.4452
140 100.18 ± 0.2462
Bupropion 20 99.81 ± 1.193
80 100.74 ± 0.6133
140 100.11 ± 0.3026
Fluoxetine 20 100.16 ± 1.135
80 99.29 ± 0.7134
140 99.65 ± 0.5267
a Mean of 3 replicates ± SD.
6 M.A. Omar et al.(Basavaiah and Sameer, 2010; Darwish, 2005; Mohamed et al.,
2007) revealed that there is no signiﬁcant difference between
them with respect to accuracy as indicated by t- and F-tests,
as shown in Table 4.
3.4.3. Precision
The United States Pharmacopoeia XXV and NF XX, 2002
was checked at three concentration levels, eight replicate mea-
surements were recorded at each concentration level; the re-
sults are summarized in Table 5. The calculated relative
standard deviations were all below 2.2% indicating excellent
precision of the proposed method.
3.4.4. Limit of detection
Topic Q2A, 1994; Topic Q2B, 1996) was calculated based on
the standard deviation of response and the slope of calibration
curve. The limit of detection is expressed as:
LOD ¼ 3r=SPlease cite this article in press as: Omar, M.A. et al., Spectroﬂuorimetric
ma through derivatization with dansyl chloride. Arabian Journal of Chwhere r is the standard deviation of intercept. S is the slope of
calibration curve.
The results are summarized in Table 2. The calculated
detection limits for all the studied drugs were less than
2.234 ng mL1 indicating good sensitivity of the proposed
method. According to USP XXV validation guidelines (The
United States Pharmacopoeia XXV and NF XX, 2002), the
calculated LOD values should be further validated by labora-
tory experiments. In our work, good results were obtained
where the calculated drug concentration by LOD equations
were actually detected in these experiments.
3.4.5. Limit of quantitation
Topic Q2A, 1994 was calculated based on standard deviation
of intercept and slope of calibration curve. In this method,
the limit of quantitation is expressed as:
LOQ ¼ 10r=S
The calculated quantitation limits for all the studied drugs
were all less than 7.445 ng mL1, as shown in Table 2,
indicating good sensitivity of the proposed method. According
to USP XXV validation guidelines (The United States
Pharmacopoeia XXV and NF XX, 2002), the calculated
LOQ values should be further validated by laboratory experi-
ments. In our work, good results were obtained where the
calculated drug concentration by LOQ equations were actually
quantitated in these experiments.
3.4.6. Speciﬁcity and interference
The speciﬁcity of the method was investigated by observation
of any interference encountered from the common tablet excip-
ients, such as talc, starch, gum acacia, lactose and magnesium
stearate. This study indicates that the presence of these excip-
ients did not interfere with the proposed method as proved by
the excellent recoveries obtained as shown in Table 6. So the
proposed method was found to be selective for the investigated
drugs in the presence of these common excipients.
3.5. Application to pharmaceutical dosage forms
The proposed method was applied for the determination of
investigated CNS drugs in commercial pharmaceutical dosage
forms. The results of proposed method were statistically com-
pared with those of reported methods (Basavaiah and Sameer,protocol for antidepressant drugs in dosage forms and human plas-
emistry (2014), http://dx.doi.org/10.1016/j.arabjc.2013.12.015
Table 6 Analysis of the investigated drugs (100.0 ng mL1) in presence of some common excipients using the proposed
spectroﬂuorimetric method with 3.71 · 105 M dansyl chloride.
Excipients Amount Added (mg) % Recoveryd ± SD
Sertraline Amineptine Paroxetine Bupropion Fluoxetine
Starch 100 99.33 ± 0.78 99.19 ± 0.72 98.98 ± 0.64 100.80 ± 0.78 99.29 ± 0.89
Lactose 50 99.70 ± 0.51 99.83 ± 0.63 99.25 ± 0.66 100.73 ± 0.71 99.12 ± 0.98
Mg stearate 10 101.25 ± 0.54 99.47 ± 0.71 99.57 ± 0.47 99.86 ± 0.33 100.22 ± 1.04
Gum acacia 10 98.84 ± 0.87 99.42 ± 0.79 99.81 ± 0.85 100.28 ± 0.89 100.98 ± 0.46
Talc 10 100.38 ± 0.59 100.07 ± 0.61 99.11 ± 0.66 100.44 ± 0.91 100.81 ± 1.08
d Mean of 3 replicates ± SD.
Spectroﬂuorimetric protocol 72010; Darwish, 2005; Mohamed et al., 2007), in respect to
accuracy and precision. The obtained mean recovery values
of the obtained amount were 99.49–100.67 ± 0.98–1.09%, as
shown in Table 7. According to t- and F-tests, no signiﬁcant
difference was found between the calculated and theoretical
values of both the proposed and the reported methods at
95% conﬁdence level. This indicates a good level of precision
and accuracy.
3.6. Application to spiked human plasma
The high sensitivity attained by the proposed method allowed
the determination of the studied drugs in spiked human plas-
ma. The concentrations of investigated CNS drugs were com-
puted from its corresponding regression equations. The
obtained mean recovery values of the obtained amount were
97.44–101.61 ± 0.425–1.78%, as shown in Table 8. Thus it
can be seen that the proposed method is suitable for the anal-
ysis of the investigated CNS in human plasma.
3.7. Analysis of cited drugs in real human plasma
Fluoxetine is metabolized into its active metabolite norﬂuoxe-
tine (Lemberger et al., 1985). Norﬂuoxetine concentrations are
approximately equal to those of the parent drug during
chronic therapy (Brunswick et al., 2002). After a ﬁxed daily
dose of ﬂuoxetine (20.0 mg day1), the concentration of the
drug and its active metabolite in the blood continues to grow
through the ﬁrst few weeks of treatment, and their steady con-
centration in the blood is achieved only after 4 weeks (Pe´rez
et al., 2001). The paroxetine is completely absorbed after oral
administration and metabolized in the liver forming threeTable 7 Statistical analysis of the results obtained using the propo
investigated drugs in pharmaceutical dosage forms.
Drug Pharmaceutical dosage forms Proposed m
Sertraline Lustral tablets 100.67 ± 1
t= 0.92 a F
Amineptine Ramixol tablets 100.04 ± 1
t= 0.20* F
Paroxetine Paxetin tablets 99.49 ± 1.0
t= 0.45 F
Bupropion Abstain tablets 100.03 ± 0
t= 0.96 F
Fluoxetine Flutin capsules 100.01 ± 0
t= 1.02 F
a Tabulated value at 95% conﬁdence limit; F= 6.338 and t= 2.306.
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ma through derivatization with dansyl chloride. Arabian Journal of Chmain metabolites: the two isomers (3S,4R)-4-(4-ﬂuorophenyl)-
3-[(4-hydroxy-3-methoxyphenoxy)methyl]-piperidine (M1) and
(3S,4R)-4-(4-ﬂuorophenyl)-3-[(3-hydroxy-4-methoxyphenoxy)
methyl]-piperidine (M2) and (3S,4R)-3-hydroxymethyl-4-(4-
ﬂuorophenyl) piperidine (M3) (Hiemke and Hartter, 2000).
Steady-state plasma paroxetine concentrations were achieved
after approximately 10 days following a 40-mg once daily dose
(Mandrioli et al., 2007). The bupropion is mainly metabolized
into hydroxybupropion. Steady state plasma level was
achieved within 5 days while its metabolites within 8 days in
healthy volunteers following a 150-mg dose of the extended-
release tablet every 12 h (Briggs et al., 1993). The sertraline
is mainly metabolized into N-desmethylsertraline. Steady state
plasma concentration level for sertraline and its metabolite
was achieved after approximately one week of a 50-mg
once-daily dosing (Mandrioli et al., 2006; Package Insert,
1992). Amineptine is mainly metabolized by beta-oxidation
of the side chain, its principle metabolites have the same struc-
ture as the parent compound except that its side chain is re-
duced to ﬁve carbon atom (Lachatre et al., 1989). Steady
state plasma level was achieved at 8th day following two
100.0 mg doses per day (Rop et al., 1990).
% recovery of investigated CNS drugs and their
metabolites in plasma was calculated by using the following
equation%Recoveryinvivo¼ðconcentrationfound=concentrationtakenÞ100
where% recoveryin vivo is % recovery for drug in real human
sample.Concentrationfound is concentration of the drug found
in the real human sample.Concentrationtaken is concentration
of the drug reported in the real human sample.sed spectroﬂuorimetric and reported methods for analysis of the
ethods ± SD (n= 5) Reported method8–10 ± SD (n= 5)
.03 101.20 ± 0.77
= 1.81 a
.09 101.18 ± 1.58
= 2.13*
5 99.86 ± 1.49
= 1.99
.99 100.68 ± 1.16
= 1.35
.98 100.59 ± 0.82
= 1.40
protocol for antidepressant drugs in dosage forms and human plas-
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Table 8 Application of the proposed method for determination of studied CNS drugs in spiked human plasma.
Drug 20 ng mL1 % Recovery a 80 ng mL1 140 ng mL1
Sertraline 97.44 ± 1.784 98.96 ± 1.573 99.13 ± 1.13
Amineptine 101.54 ± 1.32 101.61 ± 0.946 98.84 ± 0.691
Paroxetine 101.23 ± 1.39 99.85 ± 1.04 98.53 ± 0.653
Bupropion 99.72 ± 1.06 101.49 ± 0.837 99.90 ± 0.592
Fluoxetine 98.86 ± 1.15 99.08 ± 0.773 98.21 ± 0.452
a Mean of 3 replicates ± SD.
Table 9 % recoveries after application of the proposed method for determination of investigated CNS drugs and their metabolites in
real human plasma sample.
Drug Intraday assay Interday assay
Concentration Found
a % Recoveryinvivo Concentration Found
a % Recoveryinvivo
Sertraline 26.20 81.24 25.57 79.30
29.93 92.81 26.83 83.19
27.35 84.81 28.91 89.64
Mean ± SD 86.29 ± 5.92 84.04 ± 5.22
Fluoxetine 23.98 80.75 26.24 88.35
25.06 84.37 24.24 81.62
25.51 85.90 22.68 76.37
Mean ± SD 83.67 ± 2.65 82.11 ± 6.01
Paroxetine 18.55 83.13 18.12 81.15
20.58 92.23 20.36 91.24
21.61 96.82 19.55 87.62
Mean ± SD 90.73 ± 6.97 86.67 ± 5.11
Bupropion 79.26 88.31 74.69 83.21
81.34 90.62 80.01 89.14
84.89 94.58 86.01 95.82
Mean ± SD 91.17 ± 3.17 89.39 ± 6.31
Amineptine 71.32 90.95 70.62 90.05
75.63 96.44 74.58 95.10
73.85 94.17 68.17 86.95
Mean ± SD 93.85 ± 2.76 90.69 ± 4.12
a mean of three determinations (investigated drugs with its metabolites in plasma samples) ng mL1.
Table 10 The calculated stability constant of the reaction of
the investigated drugs with dansyl chloride.
Drug Ks · 107 Log Ks
Sertraline 53.54 8.73
Amineptine 39.01 8.59
Paroxetine 33.19 8.52
Bupropion 49.94 8.69
Fluoxetine 37.81 8.58
8 M.A. Omar et al.%Recoveries after application of the proposedmethod for the
determination of the investigated CNS drugs in the real human
plasma sample by intra and inter day assay are shown in Table 9.
3.8. Determination of stability constant
The stability constant of the formed product was calculated
using the following equation (Sawyer et al., 1984):
Ks ¼ ðA=AexCxÞ=½ðCm  A=AexCxÞðCL  nA=AexCxÞn
where Ks is the stability constant of the formed product;
N= X/(1X) where X is the mole fraction of the dansyl chlo-
ride at the maximum of the continuous variation curve; A/Aex
is the ratio of the observed relative ﬂuorescence intensity to
that indicated by the tangent for the same wavelength; Cm is
the molar concentration of the dansyl chloride and CL is the
molar concentration of the investigated drugs.
Cx ¼ CL=n
The calculated stability constants for the formed ﬂuorescent
product of the investigated drugs ranged from 33.19 · 107 toPlease cite this article in press as: Omar, M.A. et al., Spectroﬂuorimetric
ma through derivatization with dansyl chloride. Arabian Journal of Ch53.54 · 107 as shown in Table 10 indicating good stability of
the formed product. The high stability constants of the formed
products may account for their high relative ﬂuorescence
intensity.
4. Conclusion
The proposed spectroﬂuorimetric method has the advantage of
being a novel, fast, highly sensitive and low cost method forprotocol for antidepressant drugs in dosage forms and human plas-
emistry (2014), http://dx.doi.org/10.1016/j.arabjc.2013.12.015
Spectroﬂuorimetric protocol 9determination of the investigated antidepressant drugs in pure
forms, pharmaceutical formulations, spiked and real human
plasma without any interference from common excipients pres-
ent or other components that may be likely in denaturized
plasma, and with minimum detection limits. Therefore, the
developed method is suitable for a routine analysis of the
investigated antidepressant drugs in quality control and clini-
cal laboratories.Acknowledgements
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